Stephen Cone Biography and Net Worth

Director of biote


Dr. Cone is a seasoned physician executive with leadership experience in multiple healthcare organizations. He is currently the President of Privia Medical Group Gulf Coast, a 350 provider multi-specialty group serving the Gulf Coast market of Texas, with offices in Houston, Austin and San Antonio. He has been a private practice OB-Gyn for 31 years and delivered over 10,000 babies during his career. He is the Market President for Privia Health, a national physician enablement company, facilitating physicians making the transition from fee for service reimbursement models to value based care and risk bearing products.  He is the Vice President of US Women’s Health Alliance, a national organization representing over 5,000 OB-Gyn providers, promoting women’s health and supporting independent OB-Gyn practices. He is Chairman of the Board for Global Women’s Health Providers, a Cedar Gate company focused on OB Bundled Payment programs. He serves on the Board of Directors of BioTe Medical, a Nasdaq company and Chairs the Advisory Board for Fannin Surgicare, an ambulatory Surgery Center. In addition to his passion for patient care and making doctor’s lives better, he enjoys hunting, fishing and college sports. He is a graduate of Texas A&M University and Baylor College of Medicine, where he also did his residency. He is married with three children.

What is Stephen Mark Cone's net worth?

The estimated net worth of Stephen Mark Cone is at least $413.33 thousand as of March 17th, 2025. Dr. Cone owns 160,829 shares of biote stock worth more than $413,331 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Cone may own. Learn More about Stephen Mark Cone's net worth.

How do I contact Stephen Mark Cone?

The corporate mailing address for Dr. Cone and other biote executives is 501 MADISON AVENUE 12TH FLOOR, NEW YORK NY, 10022. biote can also be reached via phone at 844-604-1246 and via email at [email protected]. Learn More on Stephen Mark Cone's contact information.

Has Stephen Mark Cone been buying or selling shares of biote?

Stephen Mark Cone has not been actively trading shares of biote within the last three months. Most recently, on Monday, March 17th, Stephen Mark Cone bought 38,104 shares of biote stock. The stock was acquired at an average cost of $3.88 per share, with a total value of $147,843.52. Following the completion of the transaction, the director now directly owns 160,829 shares of the company's stock, valued at $624,016.52. Learn More on Stephen Mark Cone's trading history.

Who are biote's active insiders?

biote's insider roster includes Stephen Cone (Director), and Robert Peterson (CFO). Learn More on biote's active insiders.

Are insiders buying or selling shares of biote?

In the last twelve months, biote insiders bought shares 11 times. They purchased a total of 1,412,080 shares worth more than $4,598,190.23. The most recent insider tranaction occured on May, 6th when Major Shareholder Guines Llc bought 436,037 shares worth more than $1,421,480.62. Insiders at biote own 24.0% of the company. Learn More about insider trades at biote.

Information on this page was last updated on 5/6/2025.

Stephen Mark Cone Insider Trading History at biote

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2025Buy38,104$3.88$147,843.52160,829View SEC Filing Icon  
See Full Table

Stephen Mark Cone Buying and Selling Activity at biote

This chart shows Stephen Mark Cone's buying and selling at biote by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

biote Company Overview

biote logo
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Read More

Today's Range

Now: $2.57
Low: $2.51
High: $2.60

50 Day Range

MA: $2.76
Low: $2.39
High: $3.19

2 Week Range

Now: $2.57
Low: $2.32
High: $6.90

Volume

38,858 shs

Average Volume

139,889 shs

Market Capitalization

$117.35 million

P/E Ratio

3.25

Dividend Yield

N/A

Beta

1.15